BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26295664)

  • 1. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
    Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
    AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
    Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
    Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
    Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
    Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
    Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
    Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival.
    Abramson RG; Lakomkin N; Hainline A; Kang H; Hutson MS; Arteaga CL
    AJR Am J Roentgenol; 2018 Jan; 210(1):W1-W7. PubMed ID: 29064750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy.
    Grignol VP; Smith AD; Shlapak D; Zhang X; Del Campo SM; Carson WE
    Surg Oncol; 2015 Dec; 24(4):353-8. PubMed ID: 26690825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST.
    Uhrig M; Hassel JC; Schlemmer HP; Ganten MK
    Acad Radiol; 2013 Apr; 20(4):423-9. PubMed ID: 23498982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
    Liu K; Li G; Fan C; Zhou C; Li J
    Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
    Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
    AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study.
    Gottlieb RH; Raczyk C; Hanna T; Fora A; Tan W; Nayyar R; Fakih M
    Clin Imaging; 2010; 34(3):196-202. PubMed ID: 20416484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma.
    Bonnin A; Durot C; Barat M; Djelouah M; Grange F; Mulé S; Soyer P; Hoeffel C
    Diagn Interv Imaging; 2022 Feb; 103(2):97-102. PubMed ID: 34666945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker.
    Goh V; Ganeshan B; Nathan P; Juttla JK; Vinayan A; Miles KA
    Radiology; 2011 Oct; 261(1):165-71. PubMed ID: 21813743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
    Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
    Lee HY; Lee KS; Hwang HS; Lee JW; Ahn MJ; Park K; Kim TS; Yi CA; Chung MJ
    Korean J Radiol; 2010; 11(6):618-26. PubMed ID: 21076587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.